Reliable in vitro studies require appropriate ovarian cancer cell lines

Journal of Ovarian Research

Volumn 7, Issue 1, 2014, Pages

  Jacob, Francis ^a,b   Nixdorf, Sheri ^a   Hacker, Neville F ^c   Heinzelmann Schwarz, Viola A ^a,b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c ROYAL HOSPITAL FOR WOMEN   (Australia)

Author keywords

Epithelial ovarian cancer; Immortalization; Peritoneal cancer; Primary cultures; Tubal cancer

Indexed keywords

CANCER CELL LINE; CANCER RESEARCH; DONOR; ETHNICITY; FEMALE; HEALTH CARE FACILITY; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARIAN CANCER CELL LINE; OVARY CANCER; PERITONEUM CANCER CELL LINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TISSUE CHARACTERIZATION; UTERINE TUBE CANCER CELL LINE; ANIMAL; DRUG SCREENING; GENETICS; OVARY TUMOR; PATHOLOGY; REPRODUCIBILITY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; OVARIAN NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 84902536951     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-7-60     Document Type: Review

References (41)

1. Ovarian surface epithelium: biology, endocrinology, and pathology. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC, Endocr Rev 2001 22 255 288 11294827
2. Rethinking ovarian cancer: recommendations for improving outcomes. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR, Nat Rev Cancer 2011 11 719 725 10.1038/nrc3144 21941283
3. Cancer statistics, 2013. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2013 63 11 30 10.3322/caac.21166 23335087
4. Proteogenomic studies in epithelial ovarian cancer: established knowledge and future needs. Jacob F, Goldstein DR, Fink D, Heinzelmann-Schwarz V, Biomarkers Med 2009 3 743 756 10.2217/bmm.09.48
5. Ovarian cancer update: lessons from morphology, molecules, and mice. Cho KR, Arch Pathol Lab Med 2009 133 1775 1781 19886711
6. Early events in the pathogenesis of epithelial ovarian cancer. Landen CN Jr, Birrer MJ, Sood AK, J Clin Oncol 2008 26 995 1005 10.1200/JCO.2006.07.9970 18195328
7. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Shih Ie M, Kurman RJ, Am J Pathol 2004 164 1511 1518 10.1016/S0002-9440(10)63708-X 15111296
8. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Kurman RJ, Shih Ie M, Am J Surg Pathol 2010 34 433 443 10.1097/PAS.0b013e3181cf3d79 20154587
9. The biology of ovarian cancer: new opportunities for translation. Bast RC Jr, Hennessy B, Mills GB, Nat Rev Cancer 2009 9 415 428 10.1038/nrc2644 19461667
10. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N, Science 2010 330 228 231 10.1126/science.1196333 20826764
11. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas. Samartzis EP, Noske A, Dedes KJ, Fink D, Imesch P, Int J Mol Sci 2013 14 18824 18849 10.3390/ijms140918824 24036443
12. ARID1A mutations in endometriosis-associated ovarian carcinomas. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, et al. N Engl J Med 2010 363 1532 1543 10.1056/NEJMoa1008433 20942669
13. Integrated genomic analyses of ovarian carcinoma. Cancer Genome Atlas Research N, Nature 2011 474 609 615 10.1038/nature10166 21720365
14. Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Flesken-Nikitin A, Hwang CI, Cheng CY, Michurina TV, Enikolopov G, Nikitin AY, Nature 2013 495 241 245 10.1038/nature11979 23467088
15. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Dubeau L, Gynecol Oncol 1999 72 437 442 10.1006/gyno.1998.5275 10053122
16. The cell of origin of ovarian epithelial tumours. Dubeau L, Lancet Oncol 2008 9 1191 1197 10.1016/S1470-2045(08)70308-5 19038766
17. p53 gene mutation in female genital tract carcinosarcomas (malignant mixed mullerian tumors): a clinicopathologic study of 74 cases. Costa MJ, Vogelsan J, Young LJ, Mod Pathol 1994 7 619 627 7991520
18. p53 mutant His175 identified in a newly established fallopian tube carcinoma cell line secreting interleukin 6. Runnebaum IB, Tong XW, Mobus VJ, Kieback DG, Rosenthal HE, Kreienberg R, FEBS Lett 1994 353 29 32 10.1016/0014-5793(94)00953-8 7926016
19. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Crum CP, Mol Oncol 2009 3 165 170 10.1016/j.molonc.2009.01.004 19383378
20. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y, Curr Opin Obstet Gynecol 2007 19 3 9 10.1097/GCO.0b013e328011a21f 17218844
21. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP, J Pathol 2007 211 26 35 10.1002/path.2091 17117391
22. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y, Clin Med Res 2007 5 35 44 10.3121/cmr.2007.702 17456833
23. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Salvador S, Rempel A, Soslow RA, Gilks B, Huntsman D, Miller D, Gynecol Oncol 2008 110 408 417 10.1016/j.ygyno.2008.05.010 18597838
24. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. Chen EY, Mehra K, Mehrad M, Ning G, Miron A, Mutter GL, Monte N, Quade BJ, McKeon FD, Yassin Y, Xian W, Crum CP, J Pathol 2010 222 110 116 20597068
25. Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions. Chene G, Tchirkov A, Pierre-Eymard E, Dauplat J, Raoelfils I, Cayre A, Watkin E, Vago P, Penault-Llorca F, Clin Cancer Res 2013 19 2873 2882 10.1158/1078-0432.CCR-12-3947 23589176
26. Serous carcinogenesis in the fallopian tube: a descriptive classification. Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, Lee Y, Crum CP, Int J Gynecol Pathol 2008 27 1 9 10.1097/pgp.0b013e31814b191f 18156967
27. Ki-67 labeling index as an adjunct in the diagnosis of serous tubal intraepithelial carcinoma. Kuhn E, Kurman RJ, Sehdev AS, Shih Ie M, Int J Gynecol Pathol 2012 31 416 422 10.1097/PGP.0b013e31824cbeb4 22833080
28. Ovarian surface epithelium as a source of ovarian cancers: unwarranted speculation or evidence-based hypothesis? Auersperg N, Gynecol Oncol 2013 130 246 251 10.1016/j.ygyno.2013.03.021 23558054
29. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, Drapkin R, Cancer Cell 2013 24 751 765 10.1016/j.ccr.2013.10.013 24332043
30. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Seidman JD, Zhao P, Yemelyanova A, Gynecol Oncol 2011 120 470 473 10.1016/j.ygyno.2010.11.020 21159368
31. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Nik NN, Vang R, Shih Ie M, Kurman RJ, Annu Rev Pathol 2014 9 27 45 10.1146/annurev-pathol-020712-163949 23937438
32. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, Wang TL, Shih Ie M, J Pathol 2012 226 421 426 10.1002/path.3023 21990067
33. Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004. Goodman MT, Shvetsov YB, Cancer Epidemiol Biomarkers Prev 2009 18 132 139 10.1158/1055-9965.EPI-08-0771 19124490
34. Evaluating cell lines as tumour models by comparison of genomic profiles. Domcke S, Sinha R, Levine DA, Sander C, Schultz N, Nat Commun 2013 4 2126 23839242
35. Gene Expression Signature of Normal Cell-of-Origin Predicts Ovarian Tumor Outcomes. Merritt MA, Bentink S, Schwede M, Iwanicki MP, Quackenbush J, Woo T, Agoston ES, Reinhardt F, Crum CP, Berkowitz RS, Mok SC, Witt AE, Jones MA, Wang B, Ince TA, PLoS One 2013 8 80314 10.1371/journal.pone.0080314 24303006
36. Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Im KM, Kirchhoff T, Wang X, Green T, Chow CY, Vijai J, Korn J, Gaudet MM, Fredericksen Z, Shane Pankratz V, Guiducci C, Crenshaw A, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM, Mai PL, Greene MH, Piedmonte M, Rubinstein WS, Hebon, Hogervorst FB, Rookus MA, Collee JM, Hoogerbrugge N, van Asperen CJ, Meijers-Heijboer HE, Van Roozendaal CE, Caldes T, et al. Hum Genet 2011 130 685 699 10.1007/s00439-011-1003-z 21597964
37. The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data. Bahar AY, Taylor PJ, Andrews L, Proos A, Burnett L, Tucker K, Friedlander M, Buckley MF, Cancer 2001 92 440 445 10.1002/1097-0142(20010715)92:2<440:: AID-CNCR1340>3.0.CO;2-O 11466700
38. DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, Lessey BA, Jordan VC, Bradford AP, Gynecol Oncol 2012 127 241 248 10.1016/j.ygyno.2012.06.017 22710073
39. Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa. Jager W, Horiguchi Y, Shah J, Hayashi T, Awrey S, Gust KM, Hadaschik BA, Matsui Y, Anderson S, Bell RH, Ettinger S, So AI, Gleave ME, Lee IL, Dinney CP, Tachibana M, McConkey DJ, Black PC, J Urol 2013 190 1404 1409 10.1016/j.juro.2013.03.009 23500642
40. Mycoplasmal infections alter gene expression in cultured human prostatic and cervical epithelial cells. Zhang S, Wear DJ, Lo S, FEMS Immunol Med Microbiol 2000 27 43 50 10.1111/j.1574-695X.2000.tb01410.x 10617789
41. Type-specific cell line models for type-specific ovarian cancer research. Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG, PLoS One 2013 8 72162 10.1371/journal.pone.0072162 24023729